BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia
Authors:
- Nan JiangNJNan Jiang
- Fook Tim ChewFCFook Tim Chew
- Allen Eng YeohAYAllen Eng Yeoh
- 1 March 2011
- journal article
- clinical trial
- Published by Elsevier in Experimental Hematology
- Vol. 39 (3) , 321-329.e3
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIMLeukemia, 2009
- Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in MiceCurrent Gerontology and Geriatrics Research, 2008
- How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?Trends in Cell Biology, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- Divergent Mechanisms of Glucocorticoid Resistance in Experimental Models of Pediatric Acute Lymphoblastic LeukemiaCancer Research, 2007
- Regulation of differential pro- and anti-apoptotic signaling by glucocorticoidsApoptosis, 2006
- Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)Blood, 2006
- Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology GroupBlood, 2006
- p38‐MAP kinase activation followed by BIM induction is essential for glucocorticoid‐induced apoptosis in lymphoblastic leukemia cellsFEBS Letters, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001